Telaglenastat (CB-839) is a first-in-class, selective, reversible, and orally active GLS1 inhibitor that has been investigated in several clinical trials for its potential to enhance therapeutic outcomes in RCC. This evidence concerns the gene GLS and renal cell carcinoma.